Noradrenaline Synergistically Enhances Porphyromonas gingivalis LPS and OMV-Induced Interleukin-1β Production in BV-2

Sakura Muramoto1, Sachi Shimizu1, Sumika Shirakawa1

  • 1School of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan.

Insights

Noradrenaline (NA) amplifies interleukin-1 beta (IL-1β) production by microglia in response to Porphyromonas gingivalis (Pg) virulence factors. This study reveals distinct NA-mediated pathways that enhance inflammation, potentially impacting Alzheimer's disease progression.

Area of Science:

  • Neuroimmunology
  • Microbiology
  • Molecular Biology

Background:

  • Porphyromonas gingivalis (Pg) infection is linked to systemic diseases like Alzheimer's disease (AD) and inflammation.
  • Noradrenaline (NA), a neurotransmitter, modulates microglial activation during stress, but its role in Pg-induced inflammation is unclear.

Purpose of the Study:

  • To investigate how NA regulates interleukin-1 beta (IL-1β) production by microglia stimulated with Pg virulence factors (LPS and OMVs).

Main Methods:

  • Utilized BV-2 microglia cell line stimulated with Pg LPS and OMVs.
  • Measured IL-1β mRNA, promoter activity, and protein levels.
  • Employed pharmacological inhibitors and co-immunoprecipitation.
  • Applied AlphaFold2 for structural modeling.

Main Results:

  • NA dose-dependently enhanced IL-1β production up to 20-fold.
  • NA synergistically augmented Pg LPS-induced IL-1β via the β2 adrenergic receptor (Aβ2R)/AP-1 and TLR2/NF-κB pathways.
  • Cross-coupling of NF-κB p65 and AP-1 c-Fos enhanced IL-1β promoter activity.
  • NA synergistically enhanced OMV-induced IL-1β via the Aβ2R/Epac pathway, promoting phagosome maturation.

Conclusions:

  • NA synergistically enhances microglial IL-1β production in response to Pg LPS and OMVs through distinct molecular mechanisms.
  • Findings elucidate novel neuroinflammatory pathways relevant to AD pathogenesis and Pg infection.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
700
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.3K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
638
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.3K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K